Becton, Dickinson and Company $BDX Shares Purchased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Becton, Dickinson and Company by 18.5% during the first quarter, owning 929,180 shares valued at approximately $212.8 million.
• Becton, Dickinson reported a 10.4% year-over-year revenue increase, totaling $5.51 billion, with earnings per share of $3.68, surpassing analysts' expectations.
• The company recently announced a quarterly dividend of $1.04, providing an annualized yield of 2.2%, to be paid to shareholders on September 30th.

Goldman Sachs Group Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 18.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 929,180 shares of the medical instruments supplier's stock after purchasing an additional 145,247 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.32% of Becton, Dickinson and Company worth $212,838,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Saudi Central Bank acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at about $26,000. Smallwood Wealth Investment Management LLC acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at about $27,000. REAP Financial Group LLC increased its holdings in shares of Becton, Dickinson and Company by 75.3% during the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at about $29,000. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director owned 22,226 shares in the company, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 2,965 shares of company stock worth $551,536 in the last quarter. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded up $0.51 during mid-day trading on Tuesday, hitting $186.25. The company had a trading volume of 1,211,488 shares, compared to its average volume of 1,651,059. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company's fifty day moving average is $186.95 and its 200-day moving average is $190.95. The company has a market capitalization of $53.38 billion, a price-to-earnings ratio of 33.50, a P/E/G ratio of 1.50 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. During the same quarter last year, the firm posted $3.50 EPS. The business's revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 74.82%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BDX shares. Barclays dropped their target price on Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Wells Fargo & Company upped their target price on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research report on Friday, August 8th. Piper Sandler reiterated a "neutral" rating and issued a $200.00 target price (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wall Street Zen upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their target price for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Four investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.